A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Healthy Subjects Clinical Trial

Official title:

A Double-blinded, Randomized, Controlled, Single Ascending Dose Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03698305
• Other study ID #: 5354-CL-0001
• Status: Completed
• Phase: Phase 1
• Start date: October 25, 2018
• Est. completion date: May 20, 2019

Study information

• Verified date: April 2020
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the safety and tolerability of ASP5354 administered intravenously as a single dose to healthy subjects. This study will also assess the single dose pharmacokinetics of ASP5354 in plasma and urine.

Description:

This is a study comprising of 5 cohorts (cohorts 1 to 5) of 6 healthy subjects in each cohort (4 in each ASP5354 cohort and 2 in each placebo cohort). If the data from cohorts 1 to 3 are sufficient to characterize safety, tolerability and pharmacokinetics and the assessed doses reach the expected urine ASP5354 concentration, the study may be ended without running the fourth or fifth cohorts.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 20, 2019
• Est. primary completion date: May 20, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• A female subject is eligible to participate if she is not pregnant and at least one of the following conditions applies:

• Not a woman of childbearing potential (WOCBP). OR

• A WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 30 days after the final investigational product (IP) administration.

• Female subject must agree not to breastfeed starting at screening, throughout the study period and for 30 days after the final IP administration.

• Female subject must not donate ova starting at screening, throughout the study period and for 30 days after the final IP administration.

• Male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 30 days after the final IP administration.

• Male subject must not donate sperm during the treatment period and for at least 30 days after the final IP administration.

• Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom with spermicide for the duration of the pregnancy or time the partner is breastfeeding throughout the study period and for 30 days after the final IP administration.

• Subject agrees not to participate in another interventional study while participating in the present study.

• Subject has a body mass index range of 18.5 to 32.0 kg/m2, inclusive, and weighs > 50 kg (for males) or > 40 kg (for females) at screening.

Exclusion Criteria:

• Subject has signs of urinary tract infection, abnormalities or disease or has had operational interventions on the urinary tract.

• Subject has received any IP within 28 days or 5 half-lives (if known), whichever is longer, prior to screening.

• Female subject who has been pregnant within 6 months prior to screening or breastfeeding within 3 months prior to screening.

• Subject has a known or suspected hypersensitivity to ASP5354 or any components of the formulation used.

• Subject has had previous exposure to ASP5354.

• Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma glutamyl transferase and total bilirubin [TBL]) > upper limit of normal (ULN) at day -1.

• Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration.

• Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.

• Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 2 weeks prior to day -1.

• Subject has any clinically significant abnormality following the physical examination, electrocardiogram (ECG) and protocol-defined clinical laboratory tests at screening or day 1.

• Subject has a mean pulse < 45 bpm or > 90 bpm, mean systolic blood pressure > 140 mmHg or mean diastolic blood pressure > 90 mmHg at day -1.

• Subject has a mean corrected QT interval using Fridericia's formula (QTcF) > 430 msec (for males) and > 450 msec (for females) at day 1 (as determined by the ECG machine). If the mean QTcF exceeds the limits above, 1 additional triplicate (3 measurements) ECG can be taken.

• Subject has used any prescribed or nonprescribed drugs (including vitamins, oral contraceptives, hormone replacement therapy or natural and herbal remedies [e.g., St. John's Wort]) in the 2 weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) or topical dermatological products, including corticosteroid products.

• Subject has smoked or has used tobacco-containing products or nicotine or nicotine containing products in the past 6 months prior to screening or the subject tests positive for cotinine at screening or day -1.

• Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within the past 2 years prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).

• Subject has used any drugs of abuse (including but not limited to amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) within 3 months prior to day -1 or the subject tests positive for alcohol or drugs of abuse (including but not limited to amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or day -1.

• Subject has used any inducer of metabolism (e.g., barbiturates and rifampin) in the 3 months prior to day -1.

• Subject has had significant blood loss, donated 1 unit (450 mL) or more of blood or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to day -1.

• Subject has a positive serology test for hepatitis B surface antigen, hepatitis B core antibody, hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus antibodies or human immunodeficiency virus p24 antigen at screening.

• Subject has any of the renal function tests (blood urea nitrogen and creatinine) > ULN at day -1.

In such a case, the assessment may be repeated once.

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• ASP5354
Intravenous
• Placebo
Intravenous

Locations

Country	Name	City	State
United States	Covance CRU, Daytona Beach	Daytona Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Global Development, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability assessed by nature, frequency, and severity of Adverse Events (AEs)	An AE is any untoward medical occurrence in a participants administered ASP5354, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product.; AEs will be coded using MedDRA.	Up to Day 14
Primary	Number of participants with laboratory value abnormalities and/or AEs	Number of participants with potentially clinically significant laboratory values.	Up to Day 7
Primary	Number of participants with vital sign abnormalities and /or AEs	Number of participants with potentially clinically significant vital sign values.	Up to Day 7
Primary	Safety and tolerability assessed by 12-lead electrocardiogram (ECG)	12-lead ECGs will be taken after the subject has been resting in the supine position for at least 5 minutes. 12 lead ECGs will be taken in triplicate.	Up to Day 7
Primary	Number of participants with physical exam abnormalities and/or adverse events (AEs)	Number of participants with potentially clinically significant physical exam values.	Up to Day 7
Secondary	Pharmacokinetics (PK) of ASP5354 in plasma: plasma concentration at time 0 (C0)	C0 will be derived from the PK samples collected.	Before dosing on Day 1
Secondary	PK of ASP5354 in plasma: area under the concentration-time curve from time zero to 24 hours postdose (AUC0-24)	AUC0-24 will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: AUC extrapolated from time to infinity as a percentage of total area under the concentration-time curve (AUCinf)	AUCinf will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: AUC from time zero to the time of the last quantifiable concentration (AUClast)	AUClast will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: AUC extrapolated from time to infinity as a percentage of total area under the concentration-time curve (AUCinf(%extrap))	AUCinf (%extrap) will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: maximum concentration (Cmax)	Cmax will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: total body clearance of drug from plasma (CL)	CL will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: time of maximum concentration (tmax)	tmax will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: apparent terminal elimination half-life (t1/2)	t1/2 will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in plasma: volume of distribution during terminal phase (Vz)	Vz will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: amount of unchanged drug excreted into the urine (Ae)	Ae will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: percentage of dose excreted in the urine (Ae%)	Ae% will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: cumulative amount of unchanged drug excreted into the urine (CumAe)	CumAe will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: cumulative percentage of dose excreted in the urine (CumAe%)	CumAe% will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: amount of unchanged drug excreted into the urine from time zero to the time of the last quantifiable concentration (Aelast)	Aelast will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: percent of unchanged drug excreted into the urine from time zero to the time of the last quantifiable concentration (Aelast%)	Aelast% will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: renal clearance (CLR)	CLR will be derived from the PK samples collected.	Up to 24 hr after dosing
Secondary	PK of ASP5354 in urine: mean ASP5354 urine concentrations at each time point	Mean ASP5354 urine concentrations will be derived from the PK samples collected.	Up to 24 hr after dosing